/search
Features
Create a Podcast
Spreaker
Plans & Pricing
Listen
Login
Sign up
Podcast Distribution
Podcast Monetization
Podcast Analytics
Enterprise Podcasting
Podcast Recording App
Podcast App
Featured This Week
Spreaker's Prime Shows
Staff Picks
Crime
This NFL life π
Discover more
Features
Podcast Distribution
Podcast Monetization
Podcast Analytics
Enterprise Podcasting
Podcast Recording App
Podcast App
Create a Podcast
Plans & Pricing
Listen
Featured This Week
Spreaker's Prime Shows
Staff Picks
Crime
This NFL life π
Discover more
Sign up
SIGN IN
Are molecular markers just for NSCLC?
From:
GRACEcast
0
0
7 years ago
00:00
02:36
Like
Like
Download
Embed
Info
Live Chat
Comments
Medicine
,
#2013
,
#asco
,
#cancer
,
#cancergrace
,
#carcinoma
,
#cell
,
#center
,
#custom
,
#grace
,
#gracecast
,
#institute
,
#lung
,
#markers
,
#mary
,
#moffitt
,
#molecular
,
#pinder
,
#small
,
#swedish
,
#trial
Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.
Sign in to leave a message
This episode has no messages yet. Be the first to write a message!
Author
cancerGRACE Meetings
2 followers
Follow
Following
Find us on Facebook
Copyright 2021 - Spreaker Inc. a
Voxnest
Company -
Create a Podcast
- New York, NY
Privacy
Terms